Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

The Food and Drug Administration (FDA) recently approved the nasal spray Spravato for the treatment of major depression in ...

Johnson & Johnson is normally a good buy for its dividend and the stability it offers. Over the past five years, however, the stock has risen by around just 3%. This is not the type of investment ...

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The small, Ireland-based company GH Research said its inhaled version of mebufotenin — a molecular cousin to psilocybin — was ...

approved Johnson & Johnson’s nasal spray, Spravato (esketamine), to treat major depressive disorder. Oral antidepressants are the most common treatment for depression, but they don’t work for ...

In a Phase IIb trial, GH001 elicited significant drops in treatment-resistant depression. The news comes less than two weeks ...

The U.S. Food and Drug Administration has approved a nasal spray that is known to help treat depression.

The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray ... treatment is poised to change the landscape of depression management, particularly for those grappling ...

"Treatment-resistant depression can be very complicated ... Ph.D., Global Therapeutic Area Head, Neuroscience, Johnson & ...